➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Johnson and Johnson
Harvard Business School
Boehringer Ingelheim
Mallinckrodt

Last Updated: January 28, 2021

DrugPatentWatch Database Preview

ONUREG Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Onureg patents expire, and when can generic versions of Onureg launch?

Onureg is a drug marketed by Celgene Corp and is included in one NDA. There is one patent protecting this drug.

This drug has sixty-nine patent family members in thirty-four countries.

The generic ingredient in ONUREG is azacitidine. There are fifteen drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the azacitidine profile page.

US ANDA Litigation and Generic Entry Outlook for Onureg

A generic version of ONUREG was approved as azacitidine by DR REDDYS on September 16th, 2013.

  Start Trial

Summary for ONUREG
Drug patent expirations by year for ONUREG
Drug Prices for ONUREG

See drug prices for ONUREG

Pharmacology for ONUREG

US Patents and Regulatory Information for ONUREG

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Celgene Corp ONUREG azacitidine TABLET;ORAL 214120-001 Sep 1, 2020 RX Yes No   Start Trial   Start Trial Y   Start Trial
Celgene Corp ONUREG azacitidine TABLET;ORAL 214120-002 Sep 1, 2020 RX Yes Yes   Start Trial   Start Trial   Start Trial
Celgene Corp ONUREG azacitidine TABLET;ORAL 214120-001 Sep 1, 2020 RX Yes No   Start Trial   Start Trial   Start Trial
Celgene Corp ONUREG azacitidine TABLET;ORAL 214120-002 Sep 1, 2020 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
Medtronic
Dow
Baxter
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.